The French E3N Cohort Study: Progesterone Types Added to Estrogen Therapies Are Main Breast Issues

There is some science that says that estrogen drives breast cancer.

But the majority of the science says, if you read the details in the “bowels of the study”, that it is not the estrogen, but rather the combination of the type of progesterone that is added to the estrogen that drives or does not drive breast cancer.

Take the famous French E3N Cohort Study from 2008. This should be known but many. But is known by few.

The principal investigator is Agnes Fourneir PhD.

This study was done by: E3N, Nutrition, hormones et cancer: épidémiologie et prévention INSERM : ERI20, IFR69, Université Paris Sud - Paris XI, EA4045, Institut Gustave-Roussy 39 rue Camille Desmoulins 94805 Villejuif CEDEX,FR and the Department of Preventive and Predictive Medicine Istituto Nazionale Tumori, Milan,IT

Summary (Abstract)

Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms.

It is still unclear whether some are more deleterious than others regarding breast cancer risk.

The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study.